A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. - Scott RA; Freitag DF; Li L; Chu AY; Surendran P; Young R; Grarup N; Stancáková A; Chen Y; Varga TV; Yaghootkar H; Luan J; et al. (Science translational medicine, 2016)